



5 July 2022

For Immediate Release

Microbio Announces New Status as an Unlisted Public Company

Queensland's Microbio has become an unlisted public company in a move to position the biotechnology scale-up for expansion into international markets.

This move to public company status coincided with the company's recent CE Mark of approval for the use of its revolutionary Bloodstream Infection test, Microbio InfectID-BSI in Europe.

Chief Scientific Officer and co-founder Dr Flavia Huygens said the team is working to ensure Microbio is ready for its next stage of growth.

"We received a CE Mark for the InfectID-BSI test after clinical evaluation trials and we are looking forward to being in market with our tests later this year," Dr Huygens said.

Microbio has received a strong show of support from both existing and new investors in its current capital raise and expects the round to close early in the new financial year.

CEO Paul Carboon said that the strong level of interest has come at a critical stage as Microbio moves a step closer to providing its powerful diagnostic tool to clinicians across the globe.

"In addition to welcoming a number of significant new investors, our existing investors have also reaffirmed their belief in how Microbio is progressing and have topped up their investment in the company," Mr Carboon said.

The current investment round will be used to increase commercialisation resources, prepare for domestic and international manufacturing and offset anticipated initial marketing and distribution expenses for the revolutionary InfectID-BSI test.

For more information visit: <https://microbio.com.au/about/>

-ENDS-

About Microbio

Microbio is an Australian scale-up biotechnology company based in Brisbane. The team at Microbio has brought together the latest advances in bioinformatics, genomics and molecular microbiology to develop a unique and revolutionary pathogen detection test. The Microbio team is working tirelessly to deliver their game-changing new test to the millions of patients who will benefit from better pathogen diagnosis. Microbio is actively seeking partners worldwide, especially in population health and virology, who will integrate this new information into their proactive regional and corporate testing protocols. Additionally, Microbio is looking to work with pathology laboratory partners who can help deliver these highly specific results faster and to remote locations to improve health, regardless of a patient's location.

About InfectID

InfectID is a diagnostic technology that detects and identifies bacterial, fungal, and viral targets. The test targets the pathogen's DNA 'fingerprint', found at a specific point in each pathogen's genetic code. By focusing on the genetic fingerprint rather than the whole genome, the process is fast, inexpensive, highly sensitive and can be adapted to target different pathogens. The technology was refined and became the foundation of Microbio's flagship product: InfectID-Bloodstream Infection. InfectID-BSI uses real-time Polymerase Chain Reaction (qPCR) to identify sepsis-causing pathogen species directly from blood without the need for pre-culture.

Microbio Founders

Paul Carboon | Executive Director, Founder and Chief Executive Officer

Paul has 30 years of commercialisation experience in the technology sector. Paul brings deep understanding of commercial and product management as well as product development and been an executive for over 10 years. Paul has PMBOK in Project Management, GAICD, and has completed CEO Master Class and is a leader in biotechnology innovation. He currently serves on the AusMedtech national advisory group and is a member of the Australian Medtech Manufacturing Centre Advisory Group. Paul is also an Honorary Fellow of Biotechnology at Melbourne University.

Dr Flavia Huygens | Executive Director, Founder and Chief Scientific Officer

Flavia's 30-year teaching and research career has focused on molecular microbiology, with a particular focus on human pathogens. Flavia's expertise and exceptional ability to bring together emerging technology in molecular microbiology, genomics, proteomics and bioinformatics have culminated in the creation of InfectID.